Dosing of LT4 in Older Individuals
Start Date
1/31/2024
Completion Date
4/1/2028
Summary
Our overall goal is to determine the clinical consequences of allowing greater flexibility in LT4 dosing in older individuals who take LT4.
Detailed Description
Investigators will perform a randomized, parallel, double-blind clinical trial of two 6-month dosing strategies of levothyroxine (LT4) in patients aged 65 years and older who are already taking a stable dose of at least 1.2 mcg/kg/day of LT4 therapy, one to maintain a target thyroid stimulating hormone (TSH) level of 0.5-2.0 mU/L (lower TSH group) and another of a lower levothyroxine dose to achieve a target TSH of 5.5-7.0 mU/L (higher TSH group). Investigators will assess the effects of levothyroxine therapy at two different TSH targets on symptoms of hypothyroidism, mood, sleep, measures of memory and executive function, weight, lipids, and a marker of bone turnover.
Eligibility Criteria
Age Range: 65 years to No maximum
Interventions
Levothyroxine Sodium
Conditions
Locations
Penn Medicine, Smilow Translational Research Center
Philadelphia, Pennsylvania 19104
United States